Education
A provider's guide to 503B outsourcing facilities — FDA registration, cGMP requirements, and how the 503B regulatory framework differs from 503A patient-specific compounding.
Get Provider Access
Talk with our clinical team about GLP-1, hormones, aesthetics, and specialty compounding. We'll verify your credentials and get you up and running.
Schedule a Call →By scheduling, you agree to our Privacy Policy.
A 503B compounding pharmacy — formally called an outsourcing facility — is an FDA-registered facility that compounds sterile and non-sterile medications under cGMP standards. 503B facilities operate under federal FDA oversight and follow a different regulatory framework than 503A pharmacies, which compound on a patient-specific basis.
Traditional compounding pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act. They compound on a patient-by-patient basis with individual prescriptions. A 503B outsourcing facility operates under Section 503B, which grants several distinct capabilities:
503B outsourcing facilities are particularly valuable for:
Because 503B facilities are FDA-registered, they must meet cGMP standards that include:
Each model serves a different clinical role. A 503A pharmacy like Promise Pharmacy provides custom patient-specific compounded prescriptions with clinical pharmacist support, while a 503B facility operates under a different federal regulatory framework. The right choice depends on your practice model and compound needs.
For a detailed comparison: 503A vs 503B Compounding Pharmacy
FAQ